drugset / Trial / NCT01130818
First-in-Human Single Ascending Dose of GLPG0492
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral dose of GLPG0492 compared to placebo in healthy subjects. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined. Oral bioavailability (solution vs solid capsule fasting or fed) is evaluated in healthy elderly subjects.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-08
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLPG0492 | Small molecule | 25 mg | Oral |
| Subject | GLPG0492 | Small molecule | 50 mg | Oral |
| Subject | GLPG0492 | Small molecule | 120 mg | Oral |
Indications
No indication recorded.